Portfolio strategy for pharmaceutical company
EXPLOSIVE GROWTH IN THE NUMBER OF NEW PRODUCT LAUNCHES
A multinational pharmaceutical group is expecting a substantial increase in the number of new medications launched in the market. In order to guarantee the success of these new launches, Vintura has been asked to analyse the impact of these new market launches, what priorities need to be set, and what organisational measures are required.
ANALYSIS OF THE PIPELINE AND THE IMPACT ON THE ORGANISATION
We have teamed up with the client’s product experts to make an analysis of the international pipeline of products currently being developed by the group and the impact of these projects on the various departments on an annual basis, including Medical, Sales and Marketing. This served as the input for a major working session with the board, management and several internal experts. We made an inventory of the various bottlenecks and solutions for each therapeutic domain.
We worked with the client to set priorities across all domains, defined overriding measures, and drafted specific outstanding questions for each domain. Our management teams then set to work during the subsequent weeks. This has resulted in a multi-year new product launch programme supported across the organisation, at both the portfolio and detail levels, with the required changes in structure and size of the organisation and its various divisions. It is precisely this bringing together of representatives of various roles that has taught us about the existing interdependencies and has incited us to come up with solutions together to various challenges and bottlenecks.
WELL PREPARED FOR THE EXPECTED NEW LAUNCHES
The result of this project was that clients are now well prepared for the new product launches scheduled for this geographical area over the next 5-10 years. Each of the therapeutic domains and roles currently has a good idea of the workload for the next few years. In addition, the bottlenecks have been identified, along with the measures required for this process. This is particularly relevant to employee recruitment and training, and is good news for patients, as it means newly developed medications become available in the market without any delays and with the required support (i.e. information and additional facilities).
Approaching the large number of new product launches as a programme enables clients to improve their competence in this regard on a long-term basis and to achieve maximum results from each new launch.